NEWSROOM

November 16, 2023

Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients

November 15, 2023

Grifols completes Cohort 1 in clinical study of Alpha-1 15%, evaluating first-in-human subcutaneous dosing option for patients with alpha1-antitrypsin deficiency

November 13, 2023

Grifols receives FDA approval for expanded immunoglobulin purification and filling capacity at its North Carolina site

November 6, 2023

GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023

November 2, 2023

Grifols accelerates EBITDA margin expansion to 25.1% and further improves its operating performance